India

ADD (no change)

Consensus ratings*:	Buy 9	Hold 3	Sell 3
Current price:			Rs867
Target price:			Rs1,050
Previous target:			Rs1,050
Up/downside:			21.1%
InCred Research / Cor	nsensus:		12.4%
Reuters:			UTIA.NS
Bloomberg:		ι	JTIAM IN
Market cap:		US	\$1,327m
		Rs1	10,296m
Average daily turnover		ι	JS\$1.7m
		R	s142.8m
Current shares o/s:			0.0m
Free float:			46.0%
*Source: Bloomberg			

Key changes in this note

Consistent loss in market share (total as well as equity) remains a problem. The share in equity AUM dipped to ~4.02% from ~4.25% in Sep 2023.



UTI AMC

Healthy earnings despite market share loss

- UTI AMC posted a better-than-estimated 3QFY24 PAT of Rs2.03bn (our est: Rs1.63bn) amid sequential flat yields and well-managed operating expenses.
- However, the consistent loss in market share (total as well as equity) remains a problem. The share of equity AUM fell to ~4.02% from ~4.25% in Sep 2023.
- We keep our estimates intact but remain positive on UTI AMC amid the undertone of likely acquisition. We retain our ADD rating with a TP of Rs1,050.

Yields flat sequentially aided by a rise in the share of equity AUM

UTI AMC witnessed sequentially flat yields at ~17bp amid a rise in equity and exchange traded fund or ETF AUM, which resulted in a profitability beat in 3QFY24. The company posted a better-than-estimated PAT of Rs2.03bn against our estimate of Rs1.63bn amid sequential flat yields & well-managed operating expenses. UTI reported ~2.3% growth in AUM sequentially to Rs2.72tr, whereby the spurt was mainly visible in equity AUM (+2.8% qoq), which is also attributable to the recent capital market gains.

Market share trend is disappointing across portfolios

UTI AMC reported a dip in its overall market share sequentially to ~5.54% against 5.68% last quarter, despite a sequential improvement in QAAUM. Equity AUM witnessed a sequential decline in market share to ~4.02% from ~4.25% last quarter.

Privatization on cards - probability of stake acquisition from PSUs

Post-IPO, T Rowe Price International (a global investment management firm) is the largest shareholder with ~23% stake in UTI AMC. T Rowe Price also owns a major stake in UTI Trustee Company. Considering improving efficiencies of UTI AMC, T Rowe Price (already being an investment manager) can opt to buy out majority stake from public sector banks (the easiest route) and can become the promoter.

Outlook & valuation

10.0

UTI AMC is losing market share, mainly in equity schemes, but the impact on revenue yields due to the change in the Securities and Exchange Board of India or SEBI norms remains uncertain. However, even post recent run-up, asset management companies or AMCs continue to enjoy attractive risk-reward ratios. We believe SEBI's new TER (Total Expense Ratio) norms will be applicable only from FY25F. We keep our estimates intact but remain positive for the company amid the undertone of its likely acquisition. We retain our ADD rating on the stock with a target price of Rs1,050, corresponding to ~18x FY25F EPS. Key downside risks: Lower growth and industry-related risks.

Research Analyst(s)

SBI



E mayank.agarwal@incredresearch.com **Rishabh JOGANI** T (91) 22 4161 0000 E rishabh.jogani@incredresearch.com

Financial Summary	Mar-22A	Mar-23A	Mar-24F	Mar-25F	Mar-26F
Net Interest Income (Rs m)	0	0	0	0	0
Total Non-Interest Income (Rs m)	13,189	12,669	17,969	17,795	19,954
Operating Revenue (Rs m)	13,271	12,901	18,016	17,850	20,017
Total Provision Charges (Rs m)	0	0	0	0	0
Net Profit (Rs m)	5,341	4,374	8,329	7,283	8,613
Core EPS (Rs)	42.12	34.46	65.64	57.39	67.88
Core EPS Growth	8%	(18%)	90%	(13%)	18%
FD Core P/E (x)	20.58	25.15	13.21	15.10	12.77
DPS (Rs)	21.00	22.00	45.00	45.00	55.00
Dividend Yield	2.42%	2.54%	5.19%	5.19%	6.35%
BVPS (Rs)	284.4	304.8	325.6	338.2	351.3
P/BV (x)	3.05	2.84	2.66	2.56	2.47
ROE	15.6%	11.7%	20.8%	17.3%	19.7%
% Change In Core EPS Estimates					
InCred Research/Consensus EPS (x)					

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Finance Companies | India UTI AMC | January 30, 2024

InCred Equities

Figure 1: Quarterly results summary

Rsm	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	YoY (%)	QoQ (%)
Revenue from operations	2,931	4,358	2,952	3,007	4,678	4,041	4,491	52.1%	11.1%
Other income	129	41	-18	80	8	15	12		
Total revenue (Rs m)	3,060	4,399	2,934	3,087	4,686	4,056	4,502	53.5%	11.0%
Total expenditure	1,995	1,774	1,910	1,913	1,802	1,858	1,893	-0.9%	1.9%
Cost-to-income (%)	65.2%	40.3%	65.1%	62.0%	38.4%	45.8%	42.1%		
Profit before tax	1,065	2,626	1,024	1,174	2,884	2,198	2,609	154.8%	18.7%
Тах	121	597	424	317	540	370	573	35.2%	55.2%
Tax rate (%)	22.9%	22.9%	22.9%	22.9%	22.9%	22.9%	22.9%		
Profit after tax	944	2,028	600	857	2,344	1,828	2,036	239.2%	11.3%
QAAUM (Rs tr)	2.24	2.34	2.41	2.39	2.48	2.67	2.73	13.3%	2.3%
						SOURCE:	INCRED RESE	ARCH, COMPAN	NY REPORTS

Figure 2: Our revised earning	s estimates								
		FY24F		FY25F			FY26F		
Y/E Mar (Rs m)	Earlier	Revised	% change	Earlier	Revised	% change	Earlier	Revised	% change
Revenue from operations	17,142	18,016	5.1%	17,969	17,850	-0.7%	19,480	20,017	2.8%
PAT	7,643	8,329	9.0%	7,342	7,283	-0.8%	8,255	8,613	4.3%
EPS (Rs)	60.2	65.6	9.0%	57.9	57.4	-0.8%	65.0	67.9	4.3%
Dividend payout (%)	70.0	70.0	0.0%	80.0	80.0	0.0%	80.0	80.0	0.0%
QAAUM (Rs tr)	2.7	2.7	0.9%	3.2	3.2	0.9%	3.7	3.7	0.9%
	SOURCE: INCRED RESEARCH, COMPANY REPORT						NY REPORTS		


Mar-26F 19,954 20,017 11,073 11,073 11,073 11,073 11,073 (2,436)

8,637

(23)

8,613

BY THE NUMBERS



(Rsm)	Mar-22A	Mar-23A	Mar-24F	Mar-25F
Net Interest Income				
Total Non-Interest Income	13,189	12,669	17,969	17,795
Operating Revenue	13,271	12,901	18,016	17,850
Total Non-Interest Expenses	(6,303)			
Pre-provision Operating Profit	6,600	5,856	10,186	9,249
Total Provision Charges				
Operating Profit After Provisions	6,600	5,856	10,186	9,249
Pretax Income/(Loss) from Assoc.				
Operating EBIT (incl Associates)	6,600	5,856	10,186	9,249
Non-Operating Income/(Expense)				
Profit Before Tax (pre-EI)	6,600	5,856	10,186	9,249
Exceptional Items				
Pre-tax Profit	6,600	5,856	10,186	9,249
Taxation	(1,256)	(1,459)	(1,834)	(1,942)
Consolidation Adjustments & Others		. ,		
Exceptional Income - post-tax				
· · · · · ·				

5,344

5,341

(3)

4,397

(23)

4,374

8,353

8,329

(23)

7,307

(23)

7,283

Finance Companies | India UTI AMC | January 30, 2024

Profit After Tax

Net Profit

Minority Interests

Pref. & Special Div FX And Other Adj.

NELFIUIL	5,541	4,374	0,329	7,203	0,013
Recurring Net Profit					
Balance Sheet Employment					
(Rsm)	Mar-22A	Mar-23A	Mar-24F	Mar-25F	Mar-26F
Gross Loans/Cust Deposits					
Avg Loans/Avg Deposits					
Avg Liquid Assets/Avg Assets	7.9%	9.3%	9.5%	10.0%	9.4%
Avg Liquid Assets/Avg IEAs					
Net Cust Loans/Assets					
Net Cust Loans/Broad Deposits					
Equity & Provns/Gross Cust Loans					
Asset Risk Weighting					
Provision Charge/Avg Cust Loans					
Provision Charge/Avg Assets					
Total Write Offs/Average Assets					

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Finance Companies | India UTI AMC | January 30, 2024

BY THE NUMBERS...cont'd

(Rsm)	Mar-22A	Mar-23A	Mar-24F	Mar-25F	Mar-26F
Total Gross Loans					
Liquid Assets & Invst. (Current)					
Other Int. Earning Assets					
Total Gross Int. Earning Assets					
Total Provisions/Loan Loss Reserve					
Total Net Interest Earning Assets					
Intangible Assets					
Other Non-Interest Earning Assets	2,701	2,147	2,204	2,263	2,326
Total Non-Interest Earning Assets	6,108	5,699	5,827	5,960	6,096
Cash And Marketable Securities	3,983	3,572	4,595	4,492	4,368
Long-term Investments	29,782	32,479	34,103	35,808	37,599
Total Assets	39,873	41,751	44,525	46,260	48,063
Customer Interest-Bearing Liabilities					
Bank Deposits					
Interest Bearing Liabilities: Others					
Total Interest-Bearing Liabilities					
Banks Liabilities Under Acceptances					
Total Non-Interest Bearing Liabilities	3,697	3,071	3,203	3,342	3,488
Total Liabilities	3,697	3,071	3,203	3,342	3,488
Shareholders Equity	36,062	38,680	41,322	42,918	44,575
Minority Interests	114				
Total Equity	36,177	38,680	41,322	42,918	44,575
Key Ratios					
•					
	Mar-22A	Mar-23A	Mar-24F	Mar-25F	Mar-26F
Total Income Growth	a <i>i</i> a <i>i</i>	0- <i>i</i> 0 <i>i</i>		(0.00())	
Operating Profit Growth	9.1%	85.1%	39.6%	(0.9%)	12.1%
Pretax Profit Growth	9%	(11%)	74%	(9%)	20%
Net Interest To Total Income					
Cost Of Funds					
Return On Interest Earning Assets					
Net Interest Spread					
Net Interest Margin (Avg Deposits)					
Net Interest Margin (Avg RWA)					
Provisions to Pre Prov. Operating Profit					
Interest Return On Average Assets					
Effective Tax Rate	19.0%	24.9%	18.0%	21.0%	22.0%
Net Dividend Payout Ratio	49.9%	63.8%	68.6%	78.4%	81.0%
Return On Average Assets	13.96%	10.72%	19.31%	16.05%	18.26%

SOURCE: INCRED RESEARCH, COMPANY REPORTS

DISCLAIMER

This report (including the views and opinions expressed therein, and the information comprised therein) has been prepared by Incred Research Services Private Ltd.(formerly known as Earnest Innovation Partners Private Limited) (hereinafter referred to as "IRSPL"). IRSPL is registered with SEBI as a Research Analyst vide Registration No. INH000011024. Pursuant to a trademark agreement, IRSPL has adopted "Incred Equities" as its trademark for use in this report.

The term "IRSPL" shall, unless the context otherwise requires, mean IRSPL and its affiliates, subsidiaries and related companies. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject IRSPL and its affiliates/group companies to registration or licensing requirements within such jurisdictions.

This report is being supplied to you strictly on the basis that it will remain confidential. No part of this report may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means; or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of IRSPL.

The information contained in this report is prepared from data believed to be correct and reliable at the time of issue of this report.

IRSPL is not required to issue regular reports on the subject matter of this report at any frequency and it may cease to do so or change the periodicity of reports at any time. IRSPL is not under any obligation to update this report in the event of a material change to the information contained in this report. IRSPL has not any and will not accept any, obligation to (i) check or ensure that the contents of this report remain current, reliable or relevant; (ii) ensure that the content of this report constitutes all the information a prospective investor may require; (iii) ensure the adequacy, accuracy, completeness, reliability or fairness of any views, opinions and information, and accordingly, IRSPL and its affiliates/group companies (and their respective directors, associates, connected persons and/or employees) shall not be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof.

Unless otherwise specified, this report is based upon reasonable sources. Such sources will, unless otherwise specified, for market data, be market data and prices available from the main stock exchange or market where the relevant security is listed, or, where appropriate, any other market. Information on the accounts and business of company(ies) will generally be based on published statements of the company(ies), information disseminated by regulatory information services, other publicly available information and information resulting from our research. Whilst every effort is made to ensure that statements of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable as of the date of the document in which they are contained and must not be construed as a representation that the matters referred to therein will occur. Past performance is not a reliable indicator of future performance. The value of investments may go down as well as up and those investing may, depending on the investments in question, lose more than the initial investment. No report shall constitute an offer or an invitation by or on behalf of IRSPL and its affiliates/group companies to any person to buy or sell any investments.

The opinions expressed are based on information which are believed to be accurate and complete and obtained through reliable public or other nonconfidential sources at the time made. (Information barriers and other arrangements may be established where necessary to prevent conflicts of interests arising. However, the analyst(s) may receive compensation that is based on his/their coverage of company(ies) in the performance of his/their duties or the performance of his/their recommendations. In reviewing this report, an investor should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additional information is, subject to the duties of confidentiality, available on request. The report is not a "prospectus" as defined under Indian Law, including the Companies Act, 2013, and is not, and shall not be, approved by, or filed or registered with, any Indian regulator, including any Registrar of Companies in India, SEBI, any Indian stock exchange, or the Reserve Bank of India. No offer, or invitation to offer, or solicitation of subscription with respect to any such securities listed or proposed to be listed in India is being made, or intended to be made, to the public, or to any member or section of the public in India, through or pursuant to this report.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

IRSPL may have issued other reports (based on technical analysis, event specific, short term views etc.) that are inconsistent with and reach different conclusion from the information presented in this report.

Holding of Analysts/Relatives of Analysts, IRSPL and Associates of IRSPL in the covered securities, as on the date of publishing of this report

InCred Equities

Finance Companies | India UTI AMC | January 30, 2024

	Analyst/ Relative	Entity/ Associates
any financial interests in the company covered in this report (subject company) and nature of such financial interest	NO	NO
actual/beneficial ownership of 1% or more in securities of the subject company at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;	NO	NO
any other material conflict of interest at the time of publication of the research report or at the time of public appearance	NO	NO
received any compensation from the subject company in the past twelve months for investment banking or merchant banking or brokerage services or investment advisory or depository or distribution from the subject company in the last twelve months for products/services other than investment banking or merchant banking or broker- age services or investment advisory or depository or distribution from the subject company in the last twelve months	NO	NO
managed or co-managed public offering of securities for the subject company in the last twelve months	NO	NO
received any compensation or other benefits from the subject company or third party in connection with the research report	NO	NO
served as an officer, director or employee of the subject company	NO	NO
been engaged in market making activity for the subject company	NO	NO

Analyst declaration

- The analyst responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously in an unbiased manner.
- No part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations(s) or view(s) in this report or based any specific investment banking transaction.
- The analyst(s) has(have) not had any serious disciplinary action taken against him/her(them).
- The analyst, strategist, or economist does not have any material conflict of interest at the time of publication of this report.
- The analyst(s) has(have) received compensation based upon various factors, including quality, accuracy and value of research, overall firm performance, client feedback and competitive factors.

IRSPL and/or its affiliates and/or its Directors/employees may own or have positions in securities of the company(ies) covered in this report or any securities related thereto and may from time to time add to or dispose of, or may be materially interested in, any such securities.

IRSPL and/or its affiliates and/or its Directors/employees may do and seek to do business with the company(ies) covered in this research report and may from time to time (a) buy/sell the securities covered in this report, from time to time and/or (b) act as market maker or have assumed an underwriting commitment in securities of such company(ies), and/or (c) may sell them to or buy them from customers on a principal basis and/or (d) may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) and/or (e) solicit such investment, advisory or other services from any entity mentioned in thisreport and/or (f) act as a lender/borrower to such company and may earn brokerage or other compensation. However, Analysts are forbidden to acquire, on their own account or hold securities (physical or uncertificated, including derivatives) of companies in respect of which they are compiling and producing financial recommendations or in the result of which they play a key part.